Victoza Explained: How It Works and Who It's For

Victoza at a glance:

• Drug class: GLP-1 receptor agonist
• Manufacturer: Novo Nordisk
• FDA approved: 2010
• Route: subcutaneous injection (multi-dose pen)
• Typical frequency: once daily
• Half-life: approximately 13 hours
• Cash price (US): $900-$1,100/month without insurance
• Receptor target: GLP-1 receptor

Most people land on a Victoza page because they're weighing it against another option, trying to manage side effects, or trying to figure out if it's worth the money. We try to answer all three honestly here. The headline: A1c reductions of 1.0-1.5% and modest weight loss (2-3 kg). Cardiovascular benefit in LEADER.

What is Victoza?

Victoza is liraglutide dosed for type 2 diabetes — a once-daily GLP-1 receptor agonist.

Victoza is manufactured by Novo Nordisk and is a brand name for the generic compound liraglutide. Victoza was approved by the FDA in 2010. Its approved indications include type 2 diabetes, pediatric T2D (10+), cardiovascular risk reduction in T2D. Off-label use happens in clinical practice but is the prescriber's responsibility.

The drug class glp-1 receptor agonist works by acting at the GLP-1 receptor. Here's what to expect.

How Victoza Works in the Body

Victoza is liraglutide dosed for type 2 diabetes — a once-daily GLP-1 receptor agonist. The receptor target — GLP-1 receptor — drives the downstream effects users care about: a1c reductions of 1.0-1.5% and modest weight loss (2-3 kg). cardiovascular benefit in leader.

The pharmacokinetics matter for daily use. Victoza has a half-life of approximately 13 hours, which determines how often it is dosed. The standard route of administration is subcutaneous injection (multi-dose pen), and the typical schedule is once daily.

For more detail on the underlying biology, see our breakdown of how Victoza works.

Who Uses Victoza?

Victoza is most relevant for people whose situation maps to its approved indications: type 2 diabetes; pediatric T2D (10+); cardiovascular risk reduction in T2D.

People who should avoid Victoza include those with the following:

• personal or family history of medullary thyroid carcinoma
• MEN 2 syndrome

Common and Serious Side Effects

The most commonly reported side effects of Victoza include:

• nausea
• diarrhea
• headache
• vomiting

Serious risks — uncommon but worth knowing — include:

• pancreatitis
• thyroid C-cell tumors (boxed warning)

We have a more detailed breakdown in our Victoza side-effects guide.

Victoza vs Alternatives

Many patients have transitioned from Victoza to weekly agents like Ozempic or Trulicity. If you are weighing Victoza against another option, our comparison pages include Victoza Side Effects Decoded: What's Normal vs. What Isn't, What Results Should You Expect from Victoza? A Practical Guide, Victoza Price Decoded: Insurance, Coupons, and Cash-Pay Options.

Bottom Line

Treat Victoza as one tool among several. The most successful users we see treat it as part of a structured approach, not a standalone fix. Multiple randomized controlled trials support its efficacy. If you are considering Victoza, talk to a licensed clinician first — particularly if you take other medications.

Frequently Asked Questions

Related Reading

• Victoza Side Effects Decoded: What's Normal vs. What Isn't
• What Results Should You Expect from Victoza? A Practical Guide
• Victoza Price Decoded: Insurance, Coupons, and Cash-Pay Options
• Does Victoza Actually Cause Weight Loss? An Evidence Review
• What Is Ozempic? Everything You Should Know Before Starting
• Is Ozempic Safe? An Honest Look at the Side-Effect Profile

Sources

• Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). NEJM 2015;373:11.
• Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023;389:2221.
• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989.

This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.